dll3/cd3 bispecific antibody: mechanism of action
Published 4 years ago • 3.2K plays • Length 1:16
Download video MP4
Download video MP3
Similar videos
-
5:38
amg 757: dll3 targeting, half-life extended bispecific t-cell engager immuno-oncology therapy, i...
-
1:30
bispecific antibodies for r/r aggressive b-cell lymphomas
-
5:19
dll3-targeted and chemo-sensitive therapy
-
2:24
the dll3-targeting bite, tarlatamab, for the treatment of sclc
-
8:00
cd3 x cd33 bispecific antibodies redirect donor t-cells against hla loss
-
14:00
what are bispecific antibodies?
-
3:39
cd3 proteins: hot target for bispecific antibody
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
1:01
bi 764532: a novel t-cell engager for patients with dll3 sclc and nec
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
23:13
bispecific antibodies in multiple myeloma | dana-farber cancer institute
-
3:20
phase i trial of a bcma-cd3 bispecific antibody in r/r myeloma
-
5:28
regn5459, a bcma×cd3 bispecific antibody, in r/r multiple myeloma
-
7:48
glofitamab, a cd20/cd3 bispecific antibody, in the treatment of r/r dlbcl
-
3:44
phase i study of teclistamab, a humanized bcma x cd3 bispecific antibody, in relapsed/refractory mm
-
3:28
bispecific antibodies in lung cancer
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
10:54
bispecific antibody therapy
Clip.africa.com - Privacy-policy